Alteon's Alagebrium Demonstrates Promising Effects on Cardiovascular System in Phase 2a Endothelial Function Study
May 23 2005 - 11:37AM
PR Newswire (US)
Alteon's Alagebrium Demonstrates Promising Effects on
Cardiovascular System in Phase 2a Endothelial Function Study Data
Presented at Annual Scientific Meetings of The American Geriatrics
Society and The Society of Geriatric Cardiology PARSIPPANY, N.J.,
May 23 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced
today that positive data from the initial group of patients in a
Phase 2a study on endothelial function and vascular compliance were
presented recently at two scientific forums: The American
Geriatrics Society 2005 Annual Scientific Meeting and the 11th
Annual Scientific Session of The Society of Geriatric Cardiology.
The study, conducted at Johns Hopkins University School of Medicine
(JHU), demonstrated that the company's investigational drug,
alagebrium, increases arterial elasticity through the breaking of
A.G.E. crosslinks and improves endothelial function. As central
arterial stiffening and endothelial dysfunction are both risk
factors for cardiovascular disease, the authors conclude that these
effects may favorably modify cardiovascular risk in older
hypertensive subjects. The study, presented under the titles,
"Treatment with Alagebrium, a Collagen Glycation Crosslink Breaker,
Reduces Carotid Pressure Augmentation in Older Subjects with
Isolated Systolic Hypertension," and "The Effect of Vascular
Stiffness on Endothelial Dysfunction," was conducted under grants
from the National Heart, Lung and Blood Institute and the Society
of Geriatric Cardiology/Association of Subspecialty Professors by a
JHU research team led by Susan Zieman, M.D. and David Kass, M.D.
Male or female patients 50 years of age or greater (n=13), with
systolic hypertension (systolic blood pressure > 140 mm Hg and a
diastolic blood pressure < / = 95 mm Hg) received 2 weeks of
placebo run-in dosing followed by 210 mg of alagebrium twice daily
for 8 weeks. The primary purpose of the trial was to determine
whether increasing arterial elasticity by breaking A.G.E.
crosslinks improves endothelial function as assessed by evaluating
vessel distensibility and flow-mediated dilation, a dynamic test of
endothelial cell function. Results from the pilot study showed
that, when compared with baseline, carotid augmentation index, a
measure of vascular stiffness, decreased by 37.3% and augmented
pressure declined 41% (p
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Ishares Diversified Alternatives Trust (American Stock Exchange): 0 recent articles
More Alteon , News Articles